株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

英国の製薬・バイオテクノロジー分野における建設市場の分析

Pharmaceutical and Biotechnology Construction Sector Report - UK 2018-2022

発行 AMA Research 商品コード 251790
出版日 ページ情報 英文 99 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
英国の製薬・バイオテクノロジー分野における建設市場の分析 Pharmaceutical and Biotechnology Construction Sector Report - UK 2018-2022
出版日: 2018年09月26日 ページ情報: 英文 99 Pages
概要

当レポートでは、英国のライフサイエンス部門で活動する建設会社とそのサプライチェーン、およびラボ・関連製品のサプライヤーに注目して調査し、製薬、医療技術、医療・産業用バイオテクノロジー部門の市場規模、主要企業および集中地域、英国における主な製造・R&D施設の概要、サイエンス・研究用の政府資源・投資資金の分析、製薬市場が直面している課題のレビューなどをまとめてお届けします。

第1章 イントロダクション

第2章 サマリー・将来予測

第3章 市場規模・概要

  • 市場定義・市場規模・市場額
    • 世界の製薬市場
    • 英国の製薬市場
    • 医療技術部門
    • 医療バイオテクノロジー部門
    • 産業バイオテクノロジー部門
    • 製薬部門
  • 製薬/バイオテクノロジーの集中地域
    • オックスフォードシャー
    • ロンドン、ケンブリッジ、スティーブニッジ
    • 製薬製造/R&Dの地理的ロケーション
  • 英国経済に対する製薬産業の価値
    • 製薬における英国の貿易
    • NHSへの医薬品の販売
  • 英国における製薬のR&D
    • サイエンスR&D用の政府資金
    • 製薬企業のR&D投資
    • R&Dパイプライン
  • 製薬産業の市場促進因子・主な課題
    • 英国におけるR&Dの将来

第4章 製薬・バイオテクノロジー部門における主要企業/大学

  • 概要
  • 製薬企業のランキング表
    • 世界
    • 英国
  • 企業プロファイル
    • Abbott Laboratories
    • AstraZeneca
      • GlaxoSmithKline (GSK)
    • Lilly
    • Merck & Co. Inc
    • Novartis
    • Pfizer
    • Roche
    • Sanofi-Aventis
    • Teva
  • その他の製薬/バイオテクノロジー企業
    • バイオテクノロジー:治療/診断
    • バイオテクノロジーR&D
    • 製薬
    • 英国サイエンスパーク

第5章 製薬・バイオテクノロジー分野における建設活動

  • 製薬分野における資本支出
  • 製薬における建設プロジェクトのパイプライン
  • 製薬産業における建設の課題
    • 建設コスト
    • 汚染/管理の問題

第6章 製薬&バイオテクノロジー分野における建設能力と供給

  • 概要
    • 特殊クリーンルームの建設、供給およびサービス
    • 建設コンサルタント&請負業者:製薬&バイオテクノロジー部門

図表

図表

TABLES AND CHARTS

  • CHART 1: ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020 9
  • TABLE 2: GDP DATA - 2015-2018 - KEY CONSTITUENT ELEMENTS 12
  • CHART 3: INTEREST RATES AND INFLATION (CPI) FROM 2000-2022 14
  • CHART 4: PDI & SAVINGS RATIO AT CURRENT PRICES 2000-2022 15
  • TABLE 5: EXCHANGE RATE FLUCTUATIONS 2014-2020 - STERLING TO THE DOLLAR, AND THE EURO, SPOT RATES 16
  • CHART 6: CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2011 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES) 18
  • CHART 7: CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2015 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES) 18
  • CHART 8: NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) NEW WORK & RMI - CURRENT PRICES (£BN) 2011 -2020 20
  • CHART 9: NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) BY SECTOR CURRENT PRICES (£BN) 2014 -2020 21
  • CHART 10: ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020 22
  • TABLE 11: UK SCIENCE AND RESEARCH PROJECTS: FORWARD CONSTRUCTION PIPELINE 26
  • CHART 12: UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - R&D AND MANUFACTURING OPERATIONS (£M) 2009 - 2014 28
  • TABLE 13: UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS AND KEY PARTNERS 30
  • TABLE 14: AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEANROOMS (BASED ON ISO 14644-1) 37
  • CHART 15: GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN): 2011 - 2020 54
  • CHART 16: SIZE OF THE UK LIFE SCIENCES SECTOR BY TURNOVER AND NO. COMPANIES 2015 (BIOPHARMACEUTICALS AND MEDICAL TECHNOLOGY) (BY % AND VALUE £BN) 56
  • TABLE 17: BIOPHARMACEUTICAL / MEDICAL TECHNOLOGY SECTORS: MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN THE UK - MANUFACTURING, R&D, AND PACKAGING & LOGISTICS 59
  • CHART 18: UK PHARMACEUTICAL SECTOR: DISTRIBUTION OF UK MANUFACTURING AND R&D SITES 62
  • CHART 19: PHARMACEUTICAL TRADE IN THE UK: 2010- 2015 BY VALUE (£M) 68
  • TABLE 20: GOVERNMENT RESOURCE FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M) 70
  • TABLE 21: GOVERNMENT CAPITAL FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M) 72
  • TABLE 22: TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL R&D SPEND 2015 (£BN AND BY % OF TURNOVER) 74
  • TABLE 23: TOP 20 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2015 AND 2016 75
  • TABLE 24: TOP 20 GLOBAL PHARMACEUTICAL COMPANIES BY MARKET SHARE (%) 2015 83
  • TABLE 25: TOP 10 PHARMACEUTICAL COMPANIES MARKET SHARE (%) 2015 85
  • TABLE 26: ABBVIE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 86
  • TABLE 27: ASTRAZENECA - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 87
  • TABLE 28: BOEHRINGER INGELHEIM - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS 88
  • TABLE 29: GSK- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS 89
  • TABLE 30: JOHNSON & JOHNSON - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 91
  • TABLE 31: MERCK - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 92
  • TABLE 32: NOVARTIS - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 93
  • TABLE 33: PFIZER- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 95
  • TABLE 34: ROCHE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 96
  • TABLE 35: SANOFI - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS) 97
目次
Product Code: bld108

The 4th edition of the 'Pharmaceutical & Biotechnology Construction Sector Report - UK 2018-2022' focuses on the market size, value and activity in the Pharmaceutical, Medical Technology, Medical and Industrial Biotechnology sectors in the UK, the key players and geographical areas of manufacturing and R&D concentration.

Table of Contents

1. INTRODUCTION 7

  • 1.1 INTRODUCTION 7
  • 1.2 SOURCES OF INFORMATION 7

2. SUMMARY AND MARKET PROSPECTS 9

  • 2.1 SUMMARY 9
  • 2.2 UK PHARMACEUTICALS SECTOR 10

3. ECONOMIC ENVIRONMENT 12

  • 3.1 GDP 12
  • 3.2 INFLATION & INTEREST RATES 13
  • 3.3 UNEMPLOYMENT 14
  • 3.4 HOUSEHOLD CONSUMPTION 14
  • 3.5 HOUSING & CONSTRUCTION 15
  • 3.6 STERLING 16
  • 3.7 POPULATION PROFILE 16
  • 3.8 CONCLUSIONS 17

4. CONSTRUCTION ACTIVITY IN THE UK PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS 18

  • 4.1 CONSTRUCTION INDUSTRY 18
    • 4.1.1 Overall Construction Industry 18
    • 4.1.2 Non-Domestic Construction 19
  • 4.2 DEFINITION - PHARMACEUTICALS AND BIOTECHNOLOGY 22
  • 4.3 MARKET SIZE 22
    • 4.3.1 Current Situation 22
    • 4.3.2 Market Prospects 23
    • 4.3.3 Construction Pipeline 25
  • 4.4 CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR 28
  • 4.5 SCIENCE PARKS / UNIVERSITY INNOVATION CAMPUSES 29
  • 4.6 ENTERPRISE ZONES 33
  • 4.7 CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY 34
    • 4.7.1 Construction Costs 34
    • 4.7.2 Contamination Control Issues 35

5. CONSTRUCTION CAPABILITY AND SUPPLY CHAIN 41

  • 5.1 OVERVIEW OF THE SUPPLY CHAIN 41
  • 5.2 CONSTRUCTION CONSULTANTS AND CONTRACTORS 41
  • 5.3 SPECIALIST CLEANROOM CONSTRUCTION, SUPPLY AND SERVICES 50

6. PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW 54

  • 6.1 MARKET DEFINITION, SIZE AND VALUE 54
    • 6.1.1 Global Pharmaceutical Market 54
    • 6.1.2 UK Pharmaceutical Market 55
    • 6.1.3 Biopharmaceutical Sector 56
    • 6.1.4 Medical Technology Sector 57
    • 6.1.5 Digital Health Sector 57
    • 6.1.6 Genomics Sector 57
    • 6.1.7 Location of Biopharmaceutical Manufacturing Sites 57
  • 6.2 PHARMACEUTICAL / BIOTECHNOLOGY CLUSTERS 61
    • 6.2.1 Oxfordshire BioCluster 61
    • 6.2.2 London, Cambridge and Stevenage BioClusters 61
    • 6.2.3 Regional Concentration of Pharmaceutical Manufacturing/R&D 62
    • 6.2.4 Future of Pharmaceutical Manufacturing Operations in the UK 66
  • 6.3 VALUE OF PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY 68
    • 6.3.1 UK Trade in Pharmaceuticals 68
  • 6.4 SALES OF PHARMACEUTICAL DRUGS TO THE NHS 69
  • 6.5 PHARMACEUTICAL R&D IN THE UK 69
    • 6.5.1 Government Funding for Science R&D 70
    • 6.5.2 Pharmaceutical Company Investment in R&D 72
    • 6.5.3 R&D Pipeline 74
  • 6.6 MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY 76
    • 6.6.1 Key General Issues Facing the Pharmaceutical Sector 76
    • 6.6.2 Future of the UK Pharmaceutical Sector 77

7. LEADING COMPANIES IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTORS 82

  • 7.1 OVERVIEW 82
  • 7.2 PHARMACEUTICAL COMPANY LEAGUE TABLES 82
    • 7.2.1 Global 82
    • 7.2.2 UK 84
  • 7.3 COMPANY PROFILES 85
    • 7.3.1 AbbVie 85
    • 7.3.2 AstraZeneca 86
    • 7.3.3 Boehringer Ingelheim 87
    • 7.3.4 GSK 88
    • 7.3.5 Johnson & Johnson 89
    • 7.3.6 Merck 91
    • 7.3.7 Novartis 92
    • 7.3.8 Pfizer 93
    • 7.3.9 Roche 95
    • 7.3.10 Sanofi 96
  • 7.4 OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES 97
    • 7.4.1 Biotechnology - Therapeutics/Diagnostics 97
    • 7.4.2 Biotechnology R&D 98
    • 7.4.3 Pharmaceutical 99
Back to Top